{
    "url_original": "https://www.wsj.com/articles/should-regulators-decide-alzheimers-drug-aduhelm-cost-insurance-medicaid-medicare-cms-11643316405?mod=opinion_lead_pos9",
    "url": "should-regulators-decide-alzheimers-drug-aduhelm-cost-insurance-medicaid-medicare-cms-11643316405",
    "title": "Should Medicare Decide If You Can Get an Alzheimerâ€™s Drug?",
    "sub_head": "The agency that oversees the program is operating outside its legal lane to deny coverage of an innovative new therapy.",
    "category_1": "Opinion",
    "category_2": "Commentary",
    "image_1_url": "https://images.wsj.net/im-472559?width=860&height=573",
    "image_1": "im-472559.jpg",
    "time": "2022-01-27 18:28:00"
}